Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jazz Pharmaceuticals (JAZZ) and Baxter International (BAX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Jazz Pharmaceuticals (JAZZ – Research Report) and Baxter International (BAX – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jazz Pharmaceuticals (JAZZ)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Jazz Pharmaceuticals. The company’s shares closed last Tuesday at $173.83.
According to TipRanks.com, Lee is a top 100 analyst with an average return of
Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $233.00, which is a 35.0% upside from current levels. In a report released today, TipRanks – OpenAI also upgraded the stock to Buy with a $191.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Baxter International (BAX)
In a report released yesterday, Steven Silver from Argus Research maintained a Hold rating on Baxter International. The company’s shares closed last Tuesday at $20.63.
According to TipRanks.com, Silver is ranked #3502 out of 12136 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Baxter International with a $20.00 average price target, implying a -5.7% downside from current levels. In a report issued on February 12, Stifel Nicolaus also maintained a Hold rating on the stock with a $20.00 price target.
